Hospitals administering Spravato (esketamine) should carefully document manufacturer assistance to maintain accurate billing records, support compliant claims, and prevent duplicate payments. Proper documentation helps healthcare organizations distinguish between drug acquisition costs, financial assistance, and amounts billed to insurance providers.

The first step is to maintain complete records of manufacturer assistance received for Spravato. Hospitals should document the assistance program, eligibility confirmation, approval dates, applicable terms, and supporting correspondence. Records should also identify the medication supplied, quantity received, acquisition method, and any associated financial adjustments. Patient assistance information must be handled securely and in accordance with applicable privacy requirements.

Accurate coding is another essential consideration. Hospitals must verify the appropriate Spravato billing codes based on the drug supplied, administration services, payer requirements, and applicable coding guidance. Manufacturer assistance does not automatically determine which charges are billable. Providers should confirm whether assistance affects the drug's acquisition cost, patient responsibility, or amounts reported on a claim. They should also follow payer-specific rules to avoid duplicate billing or inaccurate reimbursement.

Using professional Spravato billing services can help hospitals establish consistent procedures for recording assistance, reconciling inventory, and reviewing claims before submission. Billing teams should coordinate with pharmacy staff, finance departments, and patient assistance program administrators to ensure that documentation is complete and consistent.

A comprehensive Spravato billing guide should outline the records required for each assistance arrangement, including invoices, program confirmations, medication receipt records, and financial reconciliation documents. Hospitals should retain these records according to applicable legal, contractual, and organizational retention policies.

Common Spravato billing issues arise when assistance is not recorded correctly, medication quantities do not match inventory records, or claims include charges that conflict with payer rules. Regular audits can help identify these discrepancies before they affect reimbursement.

Finally, a reliable Spravato reimbursement guide should explain how to reconcile manufacturer assistance with insurance payments, patient balances, and actual drug costs. Hospitals should verify program terms and applicable payer requirements before adjusting claims or patient charges.

Consistent documentation promotes transparency, supports compliance, and helps hospitals manage Spravato treatment costs more effectively.